David Ricks, Eli Lilly CEO (Photographer: David Paul Morris/Bloomberg via Getty Images)
October 6, 2022 02:54 PM EDT
Pharma
Marketing

Eli Lil­ly hits the gas on tirzepatide in obe­si­ty, nabs rolling sub­mis­sion for po­ten­tial block­buster in­di­ca­tion

Beth Snyder Bulik

Senior Editor

In the al­ready buzzy obe­si­ty drug mar­ket, Eli Lil­ly is the lat­est news­mak­er, nab­bing a fast-track des­ig­na­tion and rolling re­view from the FDA on Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times